Private company

Landos Biopharma, Inc.

In its 2024 annual report the company says: “We are a clinical-stage biopharmaceutical company focused on the development of novel, oral, once-daily therapeutics for patients with autoimmune diseases. Our core expertise is the development of therapeutics that target novel pathways at the interface of immunity and metabolism. Our current focus and lead product candidate is NX-13, a novel, oral, gut-selective, NLRX1 agonist.”3 It is headquartered in Blacksburg, Virginia.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersBlacksburg, Virginia1
  • Incorporated inDE2
  • Business address1800 Kraft Drive, Suite 216, Blacksburg, Va 240602
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company focused on the development of novel, oral, once-daily therapeutics for patients with autoimmune diseases. Our core expertise is the development of therapeutics that target novel pathways at the interface of immunity and metabolism. Based on our understanding of the role that cellular metabolic pathways have on modulating inflammatory responses, we aim to inhibit these inflammatory responses by changing the metabolic processes in target cells. We believe the therapeutics we develop, if approved, could have a positive impact on the quality of life of patients suffering from autoimmune and chronic inflammatory diseases.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-215.6%Operating margin4
-213.5%Net margin4
-50.4%Return on equity5
-$27.5MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Research and development100¢$41.6M

Out of $18.0M in revenue.4 The company lost money this year.

Financial statements

Revenue64$18.0M in 2021
0$5.0M$10.0M$15.0M$20.0M2020: $0$020202021: $18.0M$18.0M2021
Operating income64-$38.8M in 2021+27% since 2020
-$40.0M-$30.0M-$20.0M-$10.0M02020: -$30.7M-$30.7M20202021: -$38.8M-$38.8M2021+27%
Net income64-$38.4M in 2021+27% since 2020
-$40.0M-$30.0M-$20.0M-$10.0M02020: -$30.1M-$30.1M20202021: -$38.4M-$38.4M2021+27%
Fiscal year201920202021
Revenue$06$18.0M4
Research and development$25.3M6$41.6M4
Operating expenses$56.8M4
Operating income-$30.7M6-$38.8M4
Income before tax-$38.4M4
Net income-$30.1M6-$38.4M4
Earnings per share-$1.024
Earnings per share (diluted)-$1.024
Shares (weighted, basic)37.6M shares4
Shares (weighted, diluted)37.6M shares4

Compare Landos Biopharma, Inc. with another company

Corporate structure

Landos Biopharma, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Landos Biopharma, Inc.

  • PERCEPTIVE ADVISORS LLC Filed SC 13D/A on Landos Biopharma, Inc., latest Apr 10, 2024 (4 filings since Aug 9, 2022)
  • Xontogeny, LLC Filed SC 13D/A on Landos Biopharma, Inc., latest Apr 10, 2024 (3 filings since Aug 9, 2022)
  • Josep Bassaganya-Riera Filed SC 13G/A on Landos Biopharma, Inc., latest Feb 14, 2024 (3 filings since Feb 14, 2022)
  • RTW INVESTMENTS, LP Filed SC 13D/A on Landos Biopharma, Inc., latest Nov 3, 2022 (3 filings since Oct 6, 2022)
  • Osage University GP III, LLC Filed SC 13G on Landos Biopharma, Inc., latest Feb 3, 2022
  • Landos Biopharma, Inc. Blacksburg, Virginia

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Landos Biopharma, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$166.0K4 Dec 31, 2022$1.2M4 Dec 31, 2021−86.7%
Accumulated depreciation$166.0K4 Dec 31, 2022$541.0K4 Dec 31, 2021−69.3%
Property and equipment, net$04 Dec 31, 2022$707.0K4 Dec 31, 2021−100.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$37.5M5 Dec 31, 2023$36.6M5 Dec 31, 2022+2.3%
Marketable securities, current$05 Dec 31, 2023$7.8M5 Dec 31, 2022−100.0%

Leadership

Who has led Landos Biopharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Josep Bassaganya-Riera2021
  2. Timothy M. Mayleben2021
  3. Gregory Oakes2022–2024

Chair

  1. Josep Bassaganya-Riera2021

President

  1. Josep Bassaganya-Riera2021

Chief financial officer

  1. Patricia L. Bitar2021
2025
Board members and other officers (15)

Timeline

  1. May 23, 20248-K Shareholder vote28
  2. May 23, 20248-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights29
  3. Mar 25, 20248-K Entered a material agreement; Regulation FD disclosure30
  4. Mar 21, 20248-K Results of operations31
  5. Jan 4, 20248-K Regulation FD disclosure32
  6. Nov 21, 20238-K Regulation FD disclosure33
  7. Nov 9, 20238-K Results of operations34
  8. Sep 21, 20238-K Executive or director change35
  9. Sep 14, 20238-K Regulation FD disclosure36
  10. Aug 9, 20238-K Results of operations37
  11. May 30, 20238-K Executive or director change; Bylaws or fiscal year changed; Regulation FD disclosure38
  12. May 25, 20238-K Bylaws or fiscal year changed; Shareholder vote; Regulation FD disclosure39
  13. Jun 22, 2022New chief executive Gregory Oakes becomes CEO10
  14. Dec 21, 2021New chief executive Timothy M. Mayleben becomes CEO12
  15. Feb 3, 2021New chief executive Josep Bassaganya-Riera becomes CEO11

Calendar

When it reported results

  1. Mar 21, 2024Reported quarterly or annual results31
  2. Nov 9, 2023Reported quarterly or annual results34
  3. Aug 9, 2023Reported quarterly or annual results37
  4. May 12, 2023Reported quarterly or annual results40
  5. Mar 23, 2023Reported quarterly or annual results41
  6. Nov 10, 2022Reported quarterly or annual results42
  7. Aug 11, 2022Reported quarterly or annual results43
  8. May 12, 2022Reported quarterly or annual results44

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

143 filings to the SEC since October 2021: 4 annual reports, 8 quarterly reports, 40 major events, 51 insider forms, 14 large holders, 26 other. The latest 20:

  1. Jun 3, 202415-12G EDGAR
  2. May 23, 20244 EDGAR
  3. May 23, 20244 EDGAR
  4. May 23, 20244 EDGAR
  5. May 23, 20244 EDGAR
  6. May 23, 20244 EDGAR
  7. May 23, 20244 EDGAR
  8. May 23, 20244 EDGAR
  9. May 23, 20244 EDGAR
  10. May 23, 2024RW EDGAR
  11. May 23, 2024S-8 POS EDGAR
  12. May 23, 2024S-8 POS EDGAR
  13. May 23, 2024S-8 POS EDGAR
  14. May 23, 2024S-8 POS EDGAR
  15. May 23, 20248-K EDGAR
  16. May 23, 20248-K EDGAR
  17. May 9, 202410-Q EDGAR
  18. Apr 25, 2024DEFM14A EDGAR
  19. Apr 16, 202410-K/A EDGAR
  20. Apr 15, 2024PREM14A EDGAR

The 143 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

18 open-market trades by officers, directors and large owners since October 2021: 0 buys and 18 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 28, 2023Bassaganya-Riera Josep10% ownerSale5,720,868Form 4
Sep 23, 2022RTW INVESTMENTS, LP10% ownerSale300,000$0.69$207.0KForm 4
Dec 20, 2021Bassaganya-Riera Josep10% ownerSale33,194$4.75$157.7KForm 4
Dec 17, 2021Bassaganya-Riera Josep10% ownerSale36,000$4.84$174.2KForm 4
Dec 16, 2021Bassaganya-Riera Josep10% ownerSale24,301$5.11$124.2KForm 4
Dec 15, 2021Bassaganya-Riera Josep10% ownerSale43,000$5.02$215.9KForm 4
Dec 14, 2021Bassaganya-Riera Josep10% ownerSale42,000$5.10$214.2KForm 4
Dec 13, 2021Bassaganya-Riera Josep10% ownerSale40,000$5.37$214.8KForm 4
Dec 10, 2021Bassaganya-Riera Josep10% ownerSale40,000$5.77$230.8KForm 4
Dec 9, 2021Bassaganya-Riera Josep10% ownerSale11,162$6.26$69.9KForm 4
Dec 8, 2021Bassaganya-Riera Josep10% ownerSale25,530$6.65$169.8KForm 4
Dec 7, 2021Bassaganya-Riera Josep10% ownerSale42,000$6.58$276.4KForm 4
Dec 6, 2021Bassaganya-Riera Josep10% ownerSale36,000$6.17$222.1KForm 4
Dec 3, 2021Bassaganya-Riera Josep10% ownerSale36,000$6.15$221.4KForm 4
Dec 2, 2021Bassaganya-Riera Josep10% ownerSale29,861$6.45$192.6KForm 4
Dec 1, 2021Bassaganya-Riera Josep10% ownerSale32,237$7.01$226.0KForm 4
Nov 30, 2021Bassaganya-Riera Josep10% ownerSale35,000$7.06$247.1KForm 4
Nov 29, 2021Bassaganya-Riera Josep10% ownerSale15,430$7.58$117.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Landos Biopharma, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLandos Biopharma, Inc.1
  • CIK0001785345
  • Employer ID (EIN)81-50855351
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1800 Kraft Drive, Suite 216, Blacksburg, VA 240601
  • Phone540-818-28441
  • Shares outstanding3,125,841 as of May 3, 20249
  • Public float$5.6M as of Jun 30, 202350
  • On EDGAR sinceAug 23, 20191
  • Filings211 in all: 4 (55), 8-K (53), 3 (18), SC 13D/A (11), 10-Q (10), CORRESP (8), UPLOAD (6), 10-K (4)1
    All 36 form types

    DEFA14A (4), S-8 (4), S-8 POS (4), 5 (2), DEF 14A (2), DRS/A (2), DRSLTR (2), EFFECT (2), S-1/A (2), SC 13D (2), SC 13G (2), SC 13G/A (2), 10-K/A (1), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), ARS (1), CERT (1), D (1), DEFM14A (1), DRS (1), PRE 14A (1), PREM14A (1), RW (1), S-1 (1), S-3 (1), S-3/A (1)

  • Latest filingsAnnual report (10-K) Mar 21, 2024
    Quarterly report (10-Q) May 9, 2024
    Proxy statement (DEF 14A) Apr 19, 2023
    Latest 8-K (8-K) May 23, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50